Navigation Links
Novavax Announces Closing of $18 Million Registered Direct Offering

ROCKVILLE, Md., Aug. 1 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) announced today that it has completed the previously announced registered direct equity financing of $18 million by issuing common stock and warrants (the "units") from its existing shelf registration statement. The Company sold 6,686,650 units to certain current and new institutional shareholders and certain affiliates of the Company. Each unit was comprised of one share of common stock and a warrant to purchase 0.5 shares of common stock and was sold at a purchase price of $2.68 per unit (or $2.8425 per unit for units sold to affiliates of the Company). The warrants, which represent the right to acquire 3,343,325 shares of common stock, will be exercisable at a price of $3.62 per share and have a five year term. The Company completed the financing without using the services of a placement agent or underwriter. Net proceeds of the offering after expenses are expected to be $17.6 million.

The Company intends to use the proceeds from this offering for pre-clinical and clinical studies for its VLP-based vaccines, internal research and development programs, working capital, capital expenditures and other general corporate purposes.

This offering was made pursuant to an existing effective shelf registration statement and was made directly by the Company. A prospectus supplement and the accompanying base prospectus was filed with the Securities and Exchange Commission ("SEC") on July 29, 2008 and may be obtained at the SEC's website at

About Novavax

Novavax, Inc. is a clinical-stage biotechnology company creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company creates VLPs by genetically engineering three-dimensional, nanostructures, which incorporate immunologically important lipids and recombinant proteins.

Novavax's VLPs resemble a virus but lack the genetic material that would cause infection. Using the Company's proprietary VLP technologies, Novavax is developing vaccines to protect against H5N1 pandemic influenza, seasonal flu and other viral diseases. The Company also utilizes a unique portable manufacturing system that allows for rapid production of vaccines requiring less infrastructure and represents a potential simpler and more efficient approach to vaccine production. Additional information about Novavax is available at and in the Company's various filings with the SEC.

Forward Looking Statements Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding revenues, operating expenses, cash burn, and clinical developments and anticipated milestones are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the Company's ability to progress any product candidates in preclinical or clinical trials; the scope, rate and progress of its preclinical studies and clinical trials and other research and development activities; the results of clinical trials; even if the data from preclinical studies or clinical trials is positive, the product may not prove to be safe and efficacious; Novavax's pilot plant facility is subject to extensive validation and FDA inspections, which may result in delays and increased costs; the effect or outcome of the Company's decision to sell Estrasorb(R); the human capital and other costs Novavax will incur to exit the manufacturing facility; our ability to enter into future collaborations with industry partners and the terms, timing and success of any such collaboration; the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; our ability to obtain rights to technology; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; our ability to obtain adequate financing in the future through product licensing, co-promotional arrangements, public or private equity or debt financing or otherwise; general business conditions; competition; business abilities and judgment of personnel; and the availability of qualified personnel. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the SEC, which are available at These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward-looking statements.

SOURCE Novavax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Novavax CEO to Present at BIO CEO & Investor Conference
2. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
3. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
4. Novavax CEO to Present at the World Vaccine Congress 2008
5. Novavax Opens Its First U.S. Vaccine Plant
6. Novavax Announces Release Date of 2008 First Quarter Financial Results and Investor Conference Call
7. Novavax Reports First Quarter 2008 Financial Results
8. Novavax CEO to Present at ACUMENBioFins 5th Annual Global Healthcare Conference
9. Novavax CEO to Present at FBR Capital Markets 12th Annual Spring Investor Conference
10. Novavax CEO to Present at Piper Jaffray Europe Conference, London, UK
11. Novavax to Join Russell 3000 Index
Post Your Comments:
(Date:11/23/2015)... CHICAGO , Nov. 24, 2015 Women with ... screening CT exams face a higher risk of lung cancer ... being presented next week at the annual meeting of the ... --> --> Lung ... are classified as solid or subsolid based on their appearance ...
(Date:11/23/2015)... Cord Blood Corporation (NYSE: CO ) ("CCBC" or ... laboratory testing, hematopoietic stem cell processing, and stem cell ... for the second quarter and first half of fiscal ... --> --> Second Quarter of Fiscal ... of fiscal 2016 increased by 12.7% to RMB171.5 million ...
(Date:11/23/2015)... ... , ... Noblis, Inc., a leading provider of science, technology, and strategy services, ... Agency (NGA), has joined the Noblis NSP team as President of the organization. ... and the private sector,” said L. Roger Mason, Jr., Ph.D. , Senior VP, ...
(Date:11/23/2015)... and PISCATAWAY, New Jersey , ... Crystallographic Data Centre (CCDC) announces the launch ... Database (CSD) and the CSD-System, now complemented by ... CSD-Discovery to support the discovery of new molecules, ... CSD-Enterprise, the complete set of the CCDC,s applications ...
Breaking Biology Technology:
(Date:10/27/2015)... JOSE, Calif. , Oct. 27, 2015 Synaptics ... interface solutions, today announced that Google has adopted the ... of touch controller solutions to power its newest flagship ... 6P by Huawei. --> ... partners like Google to provide strategic collaboration in the ...
(Date:10/26/2015)... Calif. and LAS VEGAS ... Nok Nok Labs , an innovator in modern authentication ... , today announced the launch of its latest version ... unified platform enabling organizations to use standards-based authentication that ... Nok Nok S3 Authentication Suite is ideal for organizations ...
(Date:10/23/2015)... Research and Markets ( ) has announced the ... 2015-2019" report to their offering. ... recognition biometrics market to grow at a CAGR of ... --> The report, Global Voice Recognition Biometrics ... market analysis with inputs from industry experts. The report ...
Breaking Biology News(10 mins):